|
|
Profile
|
Delegates :
Toshiro Morohoshi, Ph.D. |
|
Incorporated :
January 15 , 2008 |
Paid in Capital :
60 Million yen |
Employees :
人 |
Address :
Momijigawa Building Suite. 401 2-15-8 Nihonbashi, Chuo-ku, Tokyo TOKYO
〒103-0027
|
TEL/FAX :
03-5203-0715 / |
URL：
https://www.c-pa.jp/encompanyprofile.html |
Attachment :
|
Mission/Background :
SANSHO is a bio-venture company specializing in the development of pharmaceuticals based on Lipidology using small-molecule compounds derived from natural products. |
|
Technology & Business
|
In recent years, the relationship between lipid metabolites and diseases (Lipidology) has been rapidly developing due to the dramatic advances in mass spectrometry and genetic research. Lysophosphatidic acid (LPA), one of lysolipids, has also attracted attention for its involvement in cancer cell migration and fibrosis through the discovery of specific receptors (LPA1-6).
Cyclic phosphatidic acid (cPA), which is produced at the same time as LPA and cyclized at the polar end of LPA, has been reported to inhibit cancer cell invasion, analgesia, arthritis relief, and neuronal cell death.
We found a derivative of cPA, 2-carba-cPA (2ccPA), and it was stable and highly active. 2ccPA is currently in Phase-II clinical trials overseas for knee osteoarthritis, and a clinical trial for idiopathic pulmonary fibrosis is planned to begin within 2025.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
SSO-001
|
Phase1/2
|
Indication: knee osteoarthritis (OA)
|
Acquiring license partners, pharmaceutical companies, and joint research partners such as bio-ventures
|
SSI-002
|
Preclinical
|
Indication: idiopathic pulmonary fibrosis (IPF)
|
Acquiring license partners, pharmaceutical companies, and joint research partners such as bio-ventures
|
SSG-003
|
Discovery
|
Indication: glaucoma
|
Acquiring license partners, pharmaceutical companies, and joint research partners such as bio-ventures
|
|
|
|
|
|
|
|
|
|
|